R&D Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically. López-Belmonte outlines some of those changes and how Rovi has successfully adapted, having achieved significant growth during a time of economic downturn. Many Spanish companies have disappeared or have been sold in recent years in…
Novascon Pharmaceuticals is the second fastest growing company in the OTC/dietary supplement market in Poland. Its founder shares the reasons behind this success, including his strategy to sell their main blockbuster product early in order to reinvest in the development of their portfolio. Novascon has received a lot of media…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many analysts expected no change in policy, but 2013 saw an important restructuring of the company and a return to growth.…
Internationalization José Fernández, president of the Zeltia Group, outlines the company’s strategy for developing oncology drugs through marine-based organisms with the group’s subsidiary PharmaMar. With €550 [SG1] million invested in research and development in total, Zeltia was finally able to commercialize a novel product. Would you say that this investment was worth…
Internationalization The history of AmCham Spain dates back to 1917 and has a critical part of developing bilateral relations between Spain and the United States. The company’s president, Jaime Malet, discusses AmCham Spain’s ongoing efforts to attract investment by American companies in Spain today. What are AmCham’s greatest challenges today? The…
Biotechnology Merck’s managing director discusses the importance of diversification to succeed in Poland by saying: “Nowadays, in such a dynamic environment the healthy level of diversification that Merck offers is becoming a critical factor for sustainable growth.” Despite the fact that the Polish business environment has changed significantly, access to innovation…
market access Medtronic’s country director brings some interesting perspectives on the differences between the pharma and medical device regulations in Poland by saying: “the medical device industry is discriminated against, as we do not have clear indications to obtain product reimbursement.” Nonetheless, he adds: “The medical device industry in Poland is predictable…
Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…
GMP Poland’s Main Pharmaceutical Inspector discusses the dangers behind falsified medicines and the need to control internet pharmacies. She also showcases the great power Poland holds as a manufacturing country with over 200 manufacturers. Can you please start by introducing your organization, Main Pharmaceutical Inspectorate, and explain how it fits within…
diabetes PMG Pharma, a niche player, with products concentrated in the nephrology/dialysis, injectables and diabetes areas, has concluded distribution agreements with companies from all over the world. “Many are underestimating the Chinese pharmaceutical market but I expect to see a lot of business coming from that country”, tells Horst Peter Endler…
See our Cookie Privacy Policy Here
